Aaron Kesselheim

Aaron Kesselheim, a physician, attorney, and Harvard Medical School professor, discusses the evolving landscape of healthcare regulation. He shares his insights on the implications of the end of Chevron deference for Medicare drug coverage and emphasizes the necessity of interdisciplinary expertise in policy-making. Kesselheim recounts his resignation from an FDA advisory committee over concerns regarding an Alzheimer's drug approval, highlighting transparency issues. He also advocates for stronger NIH funding and improved drug pricing negotiation to foster biomedical innovation.